FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
StageZero Life Sciences Ltd. Stock AnalysisComprehensive stock analysis for StageZero Life Sciences Ltd. (SZLS.TO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSZLS.TO
SZLS.TO
StageZero Life Sciences Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SZLS.TO
Home🔹Stocks🔹StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLS.TO•TSX

StageZero Life Sciences Ltd.

SZLS.TO•TSX
Market cap
$4.94M
Sentiment

Your view on SZLS.TO

Mkt Cap
$4.94M
Sentiment
Your view
SZLS.TO
StageZero Life Sciences Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SZLS.TO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About StageZero Life Sciences Ltd.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
James R. Howard-Tripp
Headquarters
CA
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
James R. Howard-Tripp
Headquarters
CA
Description

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News